Trial Profile
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs HIV vaccine TBC-3B (Primary) ; Smallpox vaccine
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2014 New trial record